MGteam

Are there any updates on approval of Vyvgart for seronegative MG patients?

Great news! The phase 3 trial for Vyvgart (efgartigimod) in seronegative MG showed really promising results. The study included people with MuSK-positive, LRP4-positive, and triple seronegative MG.

Here's what the trial found:

- People taking Vyvg Show Full Answer

Are there any updates on approval of Vyvgart for seronegative MG patients?

Great news! The phase 3 trial for Vyvgart (efgartigimod) in seronegative MG showed really promising results. The study included people with MuSK-positive, LRP4-positive, and triple seronegative MG.

Here's what the trial found:

- People taking Vyvgart had statistically significant and clinically meaningful improvements in daily activities like speaking, chewing, and swallowing
- The medication was well tolerated with no new safety concerns
- Side effects were similar to previous studies, including respiratory tract infections, headaches, and urinary tract infections

Based on these positive results, the drugmaker Argenx plans to submit an application to the FDA by the end of 2025 to expand approval for seronegative MG patients.

If approved, Vyvgart could become the only FcRn blocker available for people with anti-LRP4 antibodies or those who are triple seronegative - filling an important treatment gap for groups that currently have limited FDA-approved options.

This is particularly significant since there are currently no FDA-approved treatments specifically for these seronegative subtypes. Keep in touch with your healthcare provider about when this expanded approval might become available.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Vyvgart Improves Daily Function for Seronegative MG in Phase 3 Trial